Image-guided radiofrequency ablation

Techniques and results

Riccardo Lencioni, Laura Crocetti, Elena Bozzi, Dania Cioni

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Introduction Image-guided techniques for local tumor treatment have emerged as a viable therapeutic option for patients with limited hepatic malignant disease when surgery is precluded. Over the past two decades, several methods for chemical ablation or thermal tumor destruction through localized heating or freezing have been developed and clinically tested. This chapter focuses on the use of radiofrequency ablation (RFA) in the treatment of hepatocellular carcinoma (HCC) and colorectal hepatic metastases. Radiofrequency ablation, in fact, is currently established as the primary ablative modality at most institutions. Eligibility criteria A careful clinical, laboratory, and imaging assessment has to be performed in each individual patient by a multidisciplinary team to evaluate eligibility for percutaneous ablation. Laboratory tests should include measurement of serum tumor markers, such as alpha-fetoprotein for HCC and carcinoembryonic antigen for colorectal metastases, as well as a full evaluation of the patient's coagulation status. A prothrombin time ratio (normal time/patient's time) greater than 50% and a platelet count higher than 50 000 μL−1 are required to keep the risk of bleeding at an acceptably low level. The tumor staging protocol must be tailored to the kind of malignancy. In patients with HCC, it should include abdominal ultrasound (US) and computed tomography (CT) or dynamic magnetic resonance (MR) imaging, although in selected cases chest CT and bone scintigraphy may be needed to exclude extrahepatic tumor spread. Whole-body CT and positron emission tomography (PET) or PET/CT may be required to stage patients with hepatic metastases appropriately.

Original languageEnglish (US)
Title of host publicationInterventional Radiological Treatment of Liver Tumors
PublisherCambridge University Press
Pages148-166
Number of pages19
ISBN (Print)9780511575433, 9780521886871
DOIs
StatePublished - Jan 1 2008
Externally publishedYes

Fingerprint

Ablation Techniques
Hepatocellular Carcinoma
Neoplasm Metastasis
Liver
Neoplasms
Tomography
Incineration
Neoplasm Staging
Carcinoembryonic Antigen
Prothrombin Time
alpha-Fetoproteins
Tumor Biomarkers
Platelet Count
Radionuclide Imaging
Heating
Freezing
Thorax
Therapeutics
Biomarkers
Magnetic Resonance Imaging

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lencioni, R., Crocetti, L., Bozzi, E., & Cioni, D. (2008). Image-guided radiofrequency ablation: Techniques and results. In Interventional Radiological Treatment of Liver Tumors (pp. 148-166). Cambridge University Press. https://doi.org/10.1017/CBO9780511575433.010

Image-guided radiofrequency ablation : Techniques and results. / Lencioni, Riccardo; Crocetti, Laura; Bozzi, Elena; Cioni, Dania.

Interventional Radiological Treatment of Liver Tumors. Cambridge University Press, 2008. p. 148-166.

Research output: Chapter in Book/Report/Conference proceedingChapter

Lencioni, R, Crocetti, L, Bozzi, E & Cioni, D 2008, Image-guided radiofrequency ablation: Techniques and results. in Interventional Radiological Treatment of Liver Tumors. Cambridge University Press, pp. 148-166. https://doi.org/10.1017/CBO9780511575433.010
Lencioni R, Crocetti L, Bozzi E, Cioni D. Image-guided radiofrequency ablation: Techniques and results. In Interventional Radiological Treatment of Liver Tumors. Cambridge University Press. 2008. p. 148-166 https://doi.org/10.1017/CBO9780511575433.010
Lencioni, Riccardo ; Crocetti, Laura ; Bozzi, Elena ; Cioni, Dania. / Image-guided radiofrequency ablation : Techniques and results. Interventional Radiological Treatment of Liver Tumors. Cambridge University Press, 2008. pp. 148-166
@inbook{fdf101a5f27e4c99a5088c53ecd8e38a,
title = "Image-guided radiofrequency ablation: Techniques and results",
abstract = "Introduction Image-guided techniques for local tumor treatment have emerged as a viable therapeutic option for patients with limited hepatic malignant disease when surgery is precluded. Over the past two decades, several methods for chemical ablation or thermal tumor destruction through localized heating or freezing have been developed and clinically tested. This chapter focuses on the use of radiofrequency ablation (RFA) in the treatment of hepatocellular carcinoma (HCC) and colorectal hepatic metastases. Radiofrequency ablation, in fact, is currently established as the primary ablative modality at most institutions. Eligibility criteria A careful clinical, laboratory, and imaging assessment has to be performed in each individual patient by a multidisciplinary team to evaluate eligibility for percutaneous ablation. Laboratory tests should include measurement of serum tumor markers, such as alpha-fetoprotein for HCC and carcinoembryonic antigen for colorectal metastases, as well as a full evaluation of the patient's coagulation status. A prothrombin time ratio (normal time/patient's time) greater than 50{\%} and a platelet count higher than 50 000 μL−1 are required to keep the risk of bleeding at an acceptably low level. The tumor staging protocol must be tailored to the kind of malignancy. In patients with HCC, it should include abdominal ultrasound (US) and computed tomography (CT) or dynamic magnetic resonance (MR) imaging, although in selected cases chest CT and bone scintigraphy may be needed to exclude extrahepatic tumor spread. Whole-body CT and positron emission tomography (PET) or PET/CT may be required to stage patients with hepatic metastases appropriately.",
author = "Riccardo Lencioni and Laura Crocetti and Elena Bozzi and Dania Cioni",
year = "2008",
month = "1",
day = "1",
doi = "10.1017/CBO9780511575433.010",
language = "English (US)",
isbn = "9780511575433",
pages = "148--166",
booktitle = "Interventional Radiological Treatment of Liver Tumors",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Image-guided radiofrequency ablation

T2 - Techniques and results

AU - Lencioni, Riccardo

AU - Crocetti, Laura

AU - Bozzi, Elena

AU - Cioni, Dania

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Introduction Image-guided techniques for local tumor treatment have emerged as a viable therapeutic option for patients with limited hepatic malignant disease when surgery is precluded. Over the past two decades, several methods for chemical ablation or thermal tumor destruction through localized heating or freezing have been developed and clinically tested. This chapter focuses on the use of radiofrequency ablation (RFA) in the treatment of hepatocellular carcinoma (HCC) and colorectal hepatic metastases. Radiofrequency ablation, in fact, is currently established as the primary ablative modality at most institutions. Eligibility criteria A careful clinical, laboratory, and imaging assessment has to be performed in each individual patient by a multidisciplinary team to evaluate eligibility for percutaneous ablation. Laboratory tests should include measurement of serum tumor markers, such as alpha-fetoprotein for HCC and carcinoembryonic antigen for colorectal metastases, as well as a full evaluation of the patient's coagulation status. A prothrombin time ratio (normal time/patient's time) greater than 50% and a platelet count higher than 50 000 μL−1 are required to keep the risk of bleeding at an acceptably low level. The tumor staging protocol must be tailored to the kind of malignancy. In patients with HCC, it should include abdominal ultrasound (US) and computed tomography (CT) or dynamic magnetic resonance (MR) imaging, although in selected cases chest CT and bone scintigraphy may be needed to exclude extrahepatic tumor spread. Whole-body CT and positron emission tomography (PET) or PET/CT may be required to stage patients with hepatic metastases appropriately.

AB - Introduction Image-guided techniques for local tumor treatment have emerged as a viable therapeutic option for patients with limited hepatic malignant disease when surgery is precluded. Over the past two decades, several methods for chemical ablation or thermal tumor destruction through localized heating or freezing have been developed and clinically tested. This chapter focuses on the use of radiofrequency ablation (RFA) in the treatment of hepatocellular carcinoma (HCC) and colorectal hepatic metastases. Radiofrequency ablation, in fact, is currently established as the primary ablative modality at most institutions. Eligibility criteria A careful clinical, laboratory, and imaging assessment has to be performed in each individual patient by a multidisciplinary team to evaluate eligibility for percutaneous ablation. Laboratory tests should include measurement of serum tumor markers, such as alpha-fetoprotein for HCC and carcinoembryonic antigen for colorectal metastases, as well as a full evaluation of the patient's coagulation status. A prothrombin time ratio (normal time/patient's time) greater than 50% and a platelet count higher than 50 000 μL−1 are required to keep the risk of bleeding at an acceptably low level. The tumor staging protocol must be tailored to the kind of malignancy. In patients with HCC, it should include abdominal ultrasound (US) and computed tomography (CT) or dynamic magnetic resonance (MR) imaging, although in selected cases chest CT and bone scintigraphy may be needed to exclude extrahepatic tumor spread. Whole-body CT and positron emission tomography (PET) or PET/CT may be required to stage patients with hepatic metastases appropriately.

UR - http://www.scopus.com/inward/record.url?scp=84927095544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927095544&partnerID=8YFLogxK

U2 - 10.1017/CBO9780511575433.010

DO - 10.1017/CBO9780511575433.010

M3 - Chapter

SN - 9780511575433

SN - 9780521886871

SP - 148

EP - 166

BT - Interventional Radiological Treatment of Liver Tumors

PB - Cambridge University Press

ER -